The US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene ...
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...
This system will become Sara and it is expected to enter the Gulf of Mexico next week. Could it impact Florida? How?
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...
It is too soon to discuss any impacts that Florida could experience from Potential Tropical Cyclone 19 / Sara.
Raising and narrowing 2024 guidance ranges: Adjusted EBITDA of $750 to $780 million and Adjusted Free Cash Flow of $265 to $285 million. Reaffirming 2025 guidance ranges: Adjusted EBITDA of $925 to $1 ...
Improvements to premium tax credits, enacted in the American Rescue Plan and extended by the Inflation Reduction Act, have ...
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...
Multibagger Stock: PTC Industries, an engineering component manufacturer, has experienced a remarkable surge in its share ...
The FDA has cleared PTC Therapeutics’ gene therapy for AADC deficiency, an ultra-rare disease that impacts the ...
PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback